Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies.

Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST.

Clin Rheumatol. 2012 Apr;31(4):631-6. doi: 10.1007/s10067-011-1895-y. Epub 2011 Nov 18.

PMID:
22147207
2.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
3.

Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.

Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Peserico A, Puglisi Guerra A, Vena GA.

Immunopharmacol Immunotoxicol. 2012 Aug;34(4):548-60. doi: 10.3109/08923973.2011.653646. Epub 2012 Feb 2. Review.

PMID:
22296031
4.

Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.

Chen Y, Sun J, Yang Y, Huang Y, Liu G.

Clin Rheumatol. 2016 Jan;35(1):1-18. doi: 10.1007/s10067-015-3115-7. Epub 2015 Nov 16. Review.

PMID:
26573205
5.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V.

JAMA. 2006 May 17;295(19):2275-85. Review. Erratum in: JAMA. 2006 Jun 7;295(21):2482.

PMID:
16705109
6.

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.

Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A.

BMC Musculoskelet Disord. 2008 Apr 17;9:52. doi: 10.1186/1471-2474-9-52. Review.

7.

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Hyrich KL, Silman AJ, Watson KD, Symmons DP.

Ann Rheum Dis. 2004 Dec;63(12):1538-43. Epub 2004 Jul 8. Review.

8.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

9.

Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.

Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG.

World J Gastroenterol. 2013 Jul 21;19(27):4344-50. doi: 10.3748/wjg.v19.i27.4344. Review.

10.

Safety of biologic therapies--an update.

Keystone EC.

J Rheumatol Suppl. 2005 Mar;74:8-12. Review.

PMID:
15742458
11.

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.

Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T.

Scand J Rheumatol. 2007 Nov-Dec;36(6):411-7. Review.

PMID:
18092260
12.

[Efficacy and security of tumor necrosis factor antagonists in the treatment of rheumatoid arthritis].

Pérez Pampín E, Gómez-Reino Carnota JJ.

Med Clin (Barc). 2008 Feb 16;130(5):179-87. Review. Spanish.

PMID:
18341834
13.

Optic neuritis occurring with anti-tumour necrosis factor alpha therapy.

Simsek I, Erdem H, Pay S, Sobaci G, Dinc A.

Ann Rheum Dis. 2007 Sep;66(9):1255-8. Epub 2007 Apr 24. Review.

14.

Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007848. doi: 10.1002/14651858.CD007848.pub2. Review.

PMID:
19821440
15.

Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.

Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R.

Pharmacotherapy. 2010 Apr;30(4):339-53. doi: 10.1592/phco.30.4.339. Review.

PMID:
20334454
16.

Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.

Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA.

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1443-51; quiz e88-9. doi: 10.1016/j.cgh.2014.01.021. Epub 2014 Jan 22. Review.

PMID:
24462626
17.

Problems encountered during anti-tumour necrosis factor therapy.

Desai SB, Furst DE.

Best Pract Res Clin Rheumatol. 2006 Aug;20(4):757-90. Review.

PMID:
16979537
18.

TNFalpha blockade in human diseases: mechanisms and future directions.

Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, Braun J, Reed E, Singh RR.

Clin Immunol. 2008 Feb;126(2):121-36. Epub 2007 Oct 3. Review.

19.

Side effects of anti-TNF therapy: current knowledge.

Antoni C, Braun J.

Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S152-7. Review.

PMID:
12463468
20.

The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications.

De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.

Lupus. 2005;14(12):931-7. Review.

PMID:
16425572

Supplemental Content

Support Center